Similar articles for PMID: 29685907

Year	Number of Results
2006	1
2007	2
2008	1
2009	3
2010	1
2012	3
2013	3
2014	4
2015	16
2016	13
2017	23
2018	17
2019	8
2020	6
2021	2
2022	3
2023	1
2024	0

1

Warning of an increased risk of vertebral fracture after stopping denosumab.

Symonds C, Kline G. Symonds C, et al. CMAJ. 2018 Apr 23;190(16):E485-E486. doi: 10.1503/cmaj.180115. CMAJ. 2018. PMID: 29685907 Free PMC article. No abstract available.

2

Clinical vertebral fractures following denosumab discontinuation.

Polyzos SA, Terpos E. Polyzos SA, et al. Endocrine. 2016 Oct;54(1):271-272. doi: 10.1007/s12020-016-1030-6. Epub 2016 Jul 8. Endocrine. 2016. PMID: 27393301 No abstract available.

3

Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.

Palacios S, Kalouche-Khalil L, Rizzoli R, Zapalowski C, Resch H, Adachi JD, Gallagher JC, Feldman RG, Kendler DL, Wang A, Wagman RB, Adami S. Palacios S, et al. Climacteric. 2015;18(6):805-12. doi: 10.3109/13697137.2015.1045484. Epub 2015 Sep 28. Climacteric. 2015. PMID: 26029985 Clinical Trial.

4

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).

Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T. Sugimoto T, et al. Osteoporos Int. 2015 Feb;26(2):765-74. doi: 10.1007/s00198-014-2964-2. Epub 2014 Nov 18. Osteoporos Int. 2015. PMID: 25403903 Clinical Trial.

5

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.

Lehmann T, Aeberli D. Lehmann T, et al. Osteoporos Int. 2017 Oct;28(10):3067-3068. doi: 10.1007/s00198-017-4108-y. Epub 2017 Jun 6. Osteoporos Int. 2017. PMID: 28589418 No abstract available.

6

Vertebral fractures after denosumab cessation.

Dupont J, Laurent MR, Dedeyne L, Luyten FP, Gielen E, Dejaeger M. Dupont J, et al. Cleve Clin J Med. 2020 Jun;87(6):337-338. doi: 10.3949/ccjm.87a.19152. Cleve Clin J Med. 2020. PMID: 32487552 Free article. No abstract available.

7

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.

Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Aubry-Rozier B, et al. Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28. Osteoporos Int. 2016. PMID: 26510845

8

Stopping Denosumab.

Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Lamy O, et al. Curr Osteoporos Rep. 2019 Feb;17(1):8-15. doi: 10.1007/s11914-019-00502-4. Curr Osteoporos Rep. 2019. PMID: 30659428 Review.

9

Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.

Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Lamy O, et al. J Clin Endocrinol Metab. 2017 Feb 1;102(2):354-358. doi: 10.1210/jc.2016-3170. J Clin Endocrinol Metab. 2017. PMID: 27732330

10

Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.

Anastasilakis AD, Yavropoulou MP, Makras P, Sakellariou GT, Papadopoulou F, Gerou S, Papapoulos SE. Anastasilakis AD, et al. Eur J Endocrinol. 2017 Jun;176(6):677-683. doi: 10.1530/EJE-16-1027. Epub 2017 Mar 10. Eur J Endocrinol. 2017. PMID: 28283537

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year